Medicus Pharma Ltd Stock EBITDA
| MDCX Stock | USD 2.75 0.05 1.79% |
Medicus Pharma Ltd fundamentals help investors to digest information that contributes to Medicus Pharma's financial success or failures. It also enables traders to predict the movement of Medicus OTC BB Equity. The fundamental analysis module provides a way to measure Medicus Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Medicus Pharma otc bb equity.
Medicus | EBITDA |
Medicus Pharma Ltd Company EBITDA Analysis
Medicus Pharma's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Medicus Pharma EBITDA | (323.24 K) |
Most of Medicus Pharma's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Medicus Pharma Ltd is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Medicus EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Medicus Pharma is extremely important. It helps to project a fair market value of Medicus OTC BB Equity properly, considering its historical fundamentals such as EBITDA. Since Medicus Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Medicus Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Medicus Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, Medicus Pharma Ltd reported earnings before interest,tax, depreciation and amortization of (323,240). This is much lower than that of the Other sector and significantly lower than that of the Other industry. The ebitda for all United States stocks is notably higher than that of the company.
Medicus EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Medicus Pharma's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the otc bb equitys which would be a good addition to a portfolio. Peer analysis of Medicus Pharma could also be used in its relative valuation, which is a method of valuing Medicus Pharma by comparing valuation metrics of similar companies.Medicus Pharma is currently under evaluation in ebitda category among its peers.
Medicus Fundamentals
| Current Valuation | 27.87 M | ||||
| Price To Earning | (0.21) X | ||||
| Price To Book | 9.31 X | ||||
| EBITDA | (323.24 K) | ||||
| Net Income | (6.78 M) | ||||
| Cash And Equivalents | 1.22 K | ||||
| Total Debt | 1.09 M | ||||
| Current Ratio | 0.53 X | ||||
| Book Value Per Share | (0.13) X | ||||
| Cash Flow From Operations | (4.16 M) | ||||
| Number Of Employees | 15 | ||||
| Beta | 5.96 | ||||
| Market Capitalization | 32.82 M | ||||
| Total Asset | 1.89 M | ||||
| Retained Earnings | (19.18 M) | ||||
| Working Capital | 805.8 K | ||||
| Net Asset | 1.89 M |
About Medicus Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medicus Pharma Ltd's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medicus Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medicus Pharma Ltd based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Medicus OTC BB Equity Analysis
When running Medicus Pharma's price analysis, check to measure Medicus Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medicus Pharma is operating at the current time. Most of Medicus Pharma's value examination focuses on studying past and present price action to predict the probability of Medicus Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medicus Pharma's price. Additionally, you may evaluate how the addition of Medicus Pharma to your portfolios can decrease your overall portfolio volatility.